US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Polaryx Therapeutics Inc

4.32

+1.9179.25%

Volume:38.33M

Turnover:164.28M

Market Cap:204.52M

PE:-24.97

High:5.05

Open:3.46

Low:3.09

Close:2.41

52wk High:48.91

52wk Low:2.20

Shares:47.34M

Float Shares:47.34M

Volume Ratio:337.91

T/O Rate:80.95%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.1730

EPS(LYR):-0.8876

ROE:--

ROA:--

PB:38.58

PE(LYR):-4.87

Loading ...

Overview Company News Filings

BRIEF-Polaryx Therapeutics Selects Contract Research Organization For Soteria Phase 2 Basket Trial

Polaryx Therapeutics Inc: Continues to Actively Work With Its Contract Research Organization (Cro) to Initiate Trial in First Half of 2026

THOMSON REUTERS

Polaryx Therapeutics selects CRO for SOTERIA Phase 2 trial

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:20 AM

Polaryx Therapeutics Announces SOTERIA Trial Launch for PLX-200 in Krabbe Disease

Polaryx Therapeutics (PLYX) Valuation Check After Sharp Single Day Share Price Decline

Simply Wall St.

Polaryx Therapeutics, Inc. trading halted, volatility trading pause

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 03:29 PM

Polaryx Therapeutics Welcomes New Members of the Board of Directors

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:54 AM

U.S. Small Caps Finish Mixed As United States Antimony Leads, Polaryx Therapeutics Lags

Top Midday Decliners

MT Newswires Live

Polaryx Therapeutics, Inc. trading resumes

Polaryx to present late-breaker data related to Soteria ahead of trial

Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Company Prepares for SOTERIA Trial Launch

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:58 PM

NASDAQ TRADE HALT IPO SECURITY RELEASED FOR QUOTATION AT 11:01 AM

Polaryx Therapeutics Reports Direct Listing on Nasdaq

MT Newswires Live

Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol “PLYX”

NASDAQ TRADE HALT REASON NOT AVAILABLE AT 04:00 AM

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PLYX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PLYX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PLYX\",,,,,undefined,":{"symbol":"PLYX","market":"US","secType":"STK","nameCN":"Polaryx Therapeutics Inc","latestPrice":4.32,"timestamp":1771348089745,"preClose":2.41,"halted":0,"volume":38325394,"delay":0,"changeRate":0.7925311203319502,"floatShares":47343297,"shares":47343300,"eps":-0.173,"marketStatus":"Trading","change":1.91,"latestTime":"02-17 12:08:10 EST","open":3.46,"high":5.05,"low":3.09,"amount":164284120.067337,"amplitude":0.813278,"askPrice":4.32,"askSize":5486,"bidPrice":4.3,"bidSize":5200,"shortable":0,"etf":0,"ttmEps":-0.173,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1771362000000},"marketStatusCode":2,"adr":0,"listingDate":1769749200000,"exchange":"NASDAQ","adjPreClose":2.41,"preHourTrading":{"tag":"盘前","latestPrice":3.46,"preClose":2.41,"latestTime":"09:29 EST","volume":4770089,"amount":19419433.006476,"timestamp":1771338599574,"change":1.05,"changeRate":0.435685,"amplitude":25.365145},"postHourTrading":{"tag":"盘后","latestPrice":2.24,"preClose":2.41,"latestTime":"19:59 EST","volume":8530,"amount":19448.5464,"timestamp":1771030753938,"change":-0.17,"changeRate":-0.070539,"amplitude":0.074689},"volumeRatio":337.913158},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PLYX\",,,,,undefined,":{"symbol":"PLYX","floatShares":47343297,"roa":"--","roe":"--","lyrEps":-0.887585,"volumeRatio":337.913158,"shares":47343300,"dividePrice":0,"high":5.05,"amplitude":0.813278,"preClose":2.41,"low":3.09,"week52Low":2.201,"pbRate":"38.58","week52High":48.91,"institutionHeld":0,"latestPrice":4.32,"committee":-0.026764,"eps":-0.173,"divideRate":0,"volume":38325394,"delay":0,"ttmEps":-0.173,"open":3.46,"prevYearClose":45,"prevWeekClose":2.41,"prevMonthClose":45,"prevQuarterClose":45,"fiveDayClose":5.93},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PLYX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PLYX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PLYX\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PLYX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PLYX","date":"2026-02-13","current":-13.930636,"percent":1,"low":-201.755192,"twenty":-126.529328,"median":-58.797227,"eighty":-25.939953,"high":-16.832147,"avg":-74.272113,"sd":55.165792,"marketCap":138242427},"quantilePoints":[{"date":"2026-01-30","current":-58.797227,"twenty":-58.797227,"median":-58.797227,"eighty":-58.797227,"marketCap":482901629},{"date":"2026-02-06","current":-92.230945,"twenty":-129.699766,"median":-109.380137,"eighty":-58.797227,"marketCap":757492752},{"date":"2026-02-13","current":-16.832147,"twenty":-126.529328,"median":-58.797227,"eighty":-25.939953,"marketCap":138242427}],"updateTime":1771336314576},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PLYX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2612796457","title":"BRIEF-Polaryx Therapeutics Selects Contract Research Organization For Soteria Phase 2 Basket Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2612796457","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612796457?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:42","pubTimestamp":1771335755,"startTime":"0","endTime":"0","summary":"BRIEF-Polaryx Therapeutics Selects Contract Research Organization For Soteria Phase 2 Basket TrialFeb 17 (Reuters) - Polaryx Therapeutics Inc PLYX.O:POLARYX THERAPEUTICS SELECTS CONTRACT RESEARCH ORGA","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nFWN3ZD0HR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLYX","BK4007"],"gpt_icon":0},{"id":"2612457184","title":"Polaryx Therapeutics Inc: Continues to Actively Work With Its Contract Research Organization (Cro) to Initiate Trial in First Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2612457184","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612457184?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:32","pubTimestamp":1771335147,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nFWN3ZD0HR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PLYX"],"gpt_icon":0},{"id":"2612576034","title":"Polaryx Therapeutics selects CRO for SOTERIA Phase 2 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2612576034","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612576034?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:30","pubTimestamp":1771335025,"startTime":"0","endTime":"0","summary":"Polaryx Therapeutics Inc. announced the selection of a contract research organization  for its SOTERIA Phase 2 basket trial. The trial will evaluate the safety, tolerability, and clinical activity of the company’s lead candidate, PLX-200, across four lysosomal storage disorders. The trial is expected to begin in the first half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polaryx Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 17, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL1xqcDq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","PLYX","BK4588","LU2095319765.USD","IE00BGHQF748.EUR","SG9999014013.SGD","SG9999014005.SGD","SG9999014021.USD","SG9999014039.USD","LU2210149790.SGD","IE00B3QW5Z07.USD","BK4007","BK4585","LU0314104364.USD","LU2210150020.SGD","BK4112","IE00BKPKM429.USD","NDAQ"],"gpt_icon":0},{"id":"2610920260","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 10:20 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2610920260","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610920260?lang=en_us&edition=fundamental","pubTime":"2026-02-12 23:20","pubTimestamp":1770909640,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 10:20 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nAQN2LM03Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLYX"],"gpt_icon":0},{"id":"2610623964","title":"Polaryx Therapeutics Announces SOTERIA Trial Launch for PLX-200 in Krabbe Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2610623964","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610623964?lang=en_us&edition=fundamental","pubTime":"2026-02-10 21:30","pubTimestamp":1770730253,"startTime":"0","endTime":"0","summary":"Polaryx Therapeutics Inc. has announced the upcoming launch of the SOTERIA trial, a clinical study to further evaluate PLX-200, an investigational therapy for Krabbe disease and other lysosomal storage disorders . The company presented new preclinical data on PLX-200 at the 22nd Annual WORLDSymposium on February 6, 2026, in San Diego. The findings demonstrated that orally administered gemfibrozil, the active compound in PLX-200, promoted anti-inflammatory gene expression and reduced neuro-inflammation in a mouse model of Krabbe disease. The SOTERIA trial is expected to begin in the first half of 2026, following a safe-to-proceed letter from the FDA received in October 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polaryx Therape","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDLb6MH49:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2095319765.USD","LU0314104364.USD","LU2210150020.SGD","IE00BKPKM429.USD","PLYX","SG9999014039.USD","BK4588","SG9999014013.SGD","SG9999014005.SGD","IE00B3QW5Z07.USD","BK4112","LU2210149790.SGD","IE00BGHQF748.EUR","NDAQ","BK4585","SG9999014021.USD"],"gpt_icon":0},{"id":"2609534505","title":"Polaryx Therapeutics (PLYX) Valuation Check After Sharp Single Day Share Price Decline","url":"https://stock-news.laohu8.com/highlight/detail?id=2609534505","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609534505?lang=en_us&edition=fundamental","pubTime":"2026-02-06 06:33","pubTimestamp":1770330825,"startTime":"0","endTime":"0","summary":"Polaryx Therapeutics (PLYX) has drawn investor attention after a sharp 28.9% single day share price decline, with the stock closing at US$16. This move comes against a year to date return of negative 54.3%.\nSee our latest analysis for Polaryx Therapeutics.\nThe sharp 28.9% single day share price return decline and the year to date share price return of 54.3% point to fading momentum, suggesting that recent moves reflect shifting risk perception more than steady longer term sentiment.\nIf...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-plyx/polaryx-therapeutics/news/polaryx-therapeutics-plyx-valuation-check-after-sharp-single","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-plyx/polaryx-therapeutics/news/polaryx-therapeutics-plyx-valuation-check-after-sharp-single","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PLYX"],"gpt_icon":0},{"id":"2609589486","title":"Polaryx Therapeutics, Inc. trading halted, volatility trading pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2609589486","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609589486?lang=en_us&edition=fundamental","pubTime":"2026-02-06 04:30","pubTimestamp":1770323416,"startTime":"0","endTime":"0","summary":"15:29 EST Polaryx (PLYX) Therapeutics, Inc. trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time,...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/polaryx-therapeutics-inc-trading-halted-volatility-trading-pause-thefly-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/polaryx-therapeutics-inc-trading-halted-volatility-trading-pause-thefly-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLYX"],"gpt_icon":0},{"id":"2609589615","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 03:29 PM","url":"https://stock-news.laohu8.com/highlight/detail?id=2609589615","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609589615?lang=en_us&edition=fundamental","pubTime":"2026-02-06 04:29","pubTimestamp":1770323345,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 03:29 PM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nAQN2LKZS0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLYX"],"gpt_icon":0},{"id":"2609430372","title":"Polaryx Therapeutics Welcomes New Members of the Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2609430372","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609430372?lang=en_us&edition=fundamental","pubTime":"2026-02-05 21:30","pubTimestamp":1770298200,"startTime":"0","endTime":"0","summary":"PARAMUS, NJ, Feb.  05, 2026  (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc.(Nasdaq: PLYX) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of novel","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/05/3232994/0/en/Polaryx-Therapeutics-Welcomes-New-Members-of-the-Board-of-Directors.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1236620750.USD","LU1236620834.HKD","BK4500","CPA","BK4008","PLYX"],"gpt_icon":0},{"id":"2608398030","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:54 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2608398030","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608398030?lang=en_us&edition=fundamental","pubTime":"2026-02-04 22:54","pubTimestamp":1770216841,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:54 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nAQN2LKPB8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLYX"],"gpt_icon":0},{"id":"2608388740","title":"U.S. Small Caps Finish Mixed As United States Antimony Leads, Polaryx Therapeutics Lags","url":"https://stock-news.laohu8.com/highlight/detail?id=2608388740","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608388740?lang=en_us&edition=fundamental","pubTime":"2026-02-04 05:21","pubTimestamp":1770153660,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of small-cap companies were mixed Tuesday, as the Russell 2000 Index gained 0.3%, while the S&P Small Cap 600 Index was down 0.1%.Among companies with a market value of $1 billion to $6.7 billion, United States Antimony Corp. was the best performer during the session, surging 23%, followed by Critical Metals Corp., which jumped 20%. Hycroft Mining Holding Corp. shares jumped 20%, Almonty Industries Inc. jumped 18%, and shares of USA Rare Earth Inc. jumped 17%.Polaryx Therapeutics Inc. was the biggest laggard, dropping 36%, followed by shares of Corvel Corp., which dropped 26%. Shares of Clarivate PLC dropped 20%, NIQ Global Intelligence PLC shares tumbled 20%, and LegalZoom.com Inc. plunged 20%.Major stock indexes in the U.S. decreased Tuesday as the Nasdaq Composite Index dropped 1.4%. Meanwhile, the S&P 500 Index fell 0.8%, and the Dow Jones Industrial Average dropped 0.3%.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UAMY","BK4168","PLYX"],"gpt_icon":1},{"id":"2608804767","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2608804767","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608804767?lang=en_us&edition=fundamental","pubTime":"2026-02-04 03:10","pubTimestamp":1770145824,"startTime":"0","endTime":"0","summary":"Gartner (IT) reported Tuesday a slump in Q4 adjusted earnings and set out a 2026 outlook below analysts' expectations.Shares slumped 21% as intraday trading volume soared to over 3.85 million from a d","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IT","BK4588","PLYX","LU0107464264.USD","BK4585","LU2517655291.USD","LU2517655374.HKD","MAMO","LU0154245756.USD","LU2362540622.SGD","LU0154245673.USD","LU2517655028.SGD","LU2362541273.HKD","BK4134","LU1814569148.SGD","LU2362541513.USD","BK4091"],"gpt_icon":0},{"id":"2608080854","title":"Polaryx Therapeutics, Inc. trading resumes","url":"https://stock-news.laohu8.com/highlight/detail?id=2608080854","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608080854?lang=en_us&edition=fundamental","pubTime":"2026-02-03 23:20","pubTimestamp":1770132011,"startTime":"0","endTime":"0","summary":"10:19 EST Polaryx (PLYX) Therapeutics, Inc. trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking f...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/polaryx-therapeutics-inc-trading-resumes-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/polaryx-therapeutics-inc-trading-resumes-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLYX"],"gpt_icon":0},{"id":"2608874516","title":"Polaryx to present late-breaker data related to Soteria ahead of trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2608874516","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608874516?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:40","pubTimestamp":1770126026,"startTime":"0","endTime":"0","summary":"Polaryx (PLYX) Therapeutics announces it will be presenting a late-breaking abstract on new data for PLX-200, an investigational therapy for the tr...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/polaryx-to-present-late-breaker-data-related-to-soteria-ahead-of-trial-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/polaryx-to-present-late-breaker-data-related-to-soteria-ahead-of-trial-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLYX"],"gpt_icon":0},{"id":"2608874153","title":"Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Company Prepares for SOTERIA Trial Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2608874153","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608874153?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:30","pubTimestamp":1770125400,"startTime":"0","endTime":"0","summary":"Oral presentation provides additional scientific rationale on Krabbe disease, one of four LSDs in the Phase 2 SOTERIA basket trial designed to evaluate the safety and clinical activity of lead drug ca","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/03/3231080/0/en/Polaryx-to-Present-Late-Breaker-Data-Related-to-SOTERIA-at-the-22nd-Annual-WORLDSymposium-as-Company-Prepares-for-SOTERIA-Trial-Launch.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLYX"],"gpt_icon":0},{"id":"2608892268","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 02:58 PM","url":"https://stock-news.laohu8.com/highlight/detail?id=2608892268","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608892268?lang=en_us&edition=fundamental","pubTime":"2026-02-03 03:58","pubTimestamp":1770062335,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 02:58 PM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nAQN2LKECK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLYX"],"gpt_icon":0},{"id":"2608893231","title":"NASDAQ TRADE HALT  IPO SECURITY RELEASED FOR QUOTATION AT 11:01 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2608893231","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608893231?lang=en_us&edition=fundamental","pubTime":"2026-02-03 00:01","pubTimestamp":1770048076,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  IPO SECURITY RELEASED FOR QUOTATION AT 11:01 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nAQN2LKD9K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLYX"],"gpt_icon":0},{"id":"2608933678","title":"Polaryx Therapeutics Reports Direct Listing on Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2608933678","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608933678?lang=en_us&edition=fundamental","pubTime":"2026-02-02 23:33","pubTimestamp":1770046430,"startTime":"0","endTime":"0","summary":"Polaryx Therapeutics said its shares will start trading on the Nasdaq Capital Market on Monday under the \"PLYX\" symbol.The clinical-stage biotech firm said it is developing therapies for rare orphan lysosomal storage disorders.Maxim Group acted as the financial advisor to the company for the direct listing, the firm said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NQmain","PLYX"],"gpt_icon":0},{"id":"2608886289","title":"Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol “PLYX”","url":"https://stock-news.laohu8.com/highlight/detail?id=2608886289","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608886289?lang=en_us&edition=fundamental","pubTime":"2026-02-02 21:30","pubTimestamp":1770039000,"startTime":"0","endTime":"0","summary":"PARAMUS, NJ, Feb.  02, 2026  (GLOBE NEWSWIRE) -- Polaryx Therapeutics (“Polaryx” or the “Company”) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/02/3230261/0/en/Polaryx-Therapeutics-Announces-Direct-Listing-on-Nasdaq-Shares-to-Begin-Trading-Under-the-Symbol-PLYX.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLYX"],"gpt_icon":0},{"id":"2608854875","title":"NASDAQ TRADE HALT  REASON NOT AVAILABLE AT 04:00 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2608854875","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608854875?lang=en_us&edition=fundamental","pubTime":"2026-02-02 17:00","pubTimestamp":1770022802,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  REASON NOT AVAILABLE AT 04:00 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nAQN2LKAPE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLYX"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":21,"code":"91000000","status":"200"}]}}